<?xml version="1.0" encoding="UTF-8"?>
<p id="Par28">Currently, there exist no safe and effective human vaccines for RSV nor RV. The major obstacle is an antigenic diversity of the more than 100 serotypes of rhinovirus, meaning that creating a successful vaccine is an extremely challenging task [
 <xref ref-type="bibr" rid="CR66">66</xref>]. In the development of the RV vaccine, promising results have been seen with a cross-reactive recombinant capsid protein in a mouse model [
 <xref ref-type="bibr" rid="CR67">67</xref>]. Recently, attention has been caught to live attenuated vaccines and subunit vaccines against RSV combined with Th1-enhancing adjuvant, although neither of them seems likely to be introduced to routine clinical practice soon [
 <xref ref-type="bibr" rid="CR68">68</xref>].
</p>
